Jane Street
RARE icon

Jane Street’s Ultragenyx Pharmaceutical RARE Stock Holding History

Jane Street’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$708K Sell
21,200
-102,900
-83% -$2.56M ﹤0.01% 7268
2026
Q1 		$2.6M Buy
124,100
+46,600
+60% +$1.05M ﹤0.01% 4605
2025
Q4 		$1.78M Sell
77,500
-50,400
-39% -$1.66M ﹤0.01% 5027
2025
Q3 		$3.85M Buy
127,900
+10,500
+9% +$315K ﹤0.01% 3818
2025
Q2 		$4.27M Buy
117,400
+24,600
+27% +$887K ﹤0.01% 3223
2025
Q1 		$3.36M Buy
92,800
+73,700
+386% +$3.07M ﹤0.01% 3550
2024
Q4 		$804K Sell
19,100
-7,500
-28% -$372K ﹤0.01% 5794
2024
Q3 		$1.48M Sell
26,600
-11,100
-29% -$565K ﹤0.01% 5078
2024
Q2 		$1.55M Sell
37,700
-13,000
-26% -$555K ﹤0.01% 4950
2024
Q1 		$2.37M Sell
50,700
-87,900
-63% -$4.15M ﹤0.01% 3826
2023
Q4 		$6.63M Buy
138,600
+122,800
+777% +$4.76M ﹤0.01% 2463
2023
Q3 		$563K Sell
15,800
-11,400
-42% -$452K ﹤0.01% 6098
2023
Q2 		$1.25M Sell
27,200
-6,800
-20% -$315K ﹤0.01% 4854
2023
Q1 		$1.36M Sell
34,000
-48,600
-59% -$2.09M ﹤0.01% 4459
2022
Q4 		$3.83M Buy
82,600
+51,800
+168% +$2.04M ﹤0.01% 2853
2022
Q3 		$1.27M Buy
30,800
+24,700
+405% +$1.27M ﹤0.01% 4979
2022
Q2 		$364K Sell
6,100
-14,100
-70% -$868K ﹤0.01% 7279
2022
Q1 		$1.47M Buy
+20,200
New +$1.41M ﹤0.01% 5346
2021
Q4 		– Sell
-16,500
Closed -$1.49M – 10686
2021
Q3 		$1.49M Buy
+16,500
New +$1.49M ﹤0.01% 5086
2021
Q2 		– Sell
-15,100
Closed -$1.72M – 10293
2021
Q1 		$1.72M Sell
15,100
-4,200
-22% -$572K ﹤0.01% 4319
2020
Q4 		$2.67M Sell
19,300
-900
-4% -$107K ﹤0.01% 2991
2020
Q3 		$1.66M Buy
20,200
+7,900
+64% +$655K ﹤0.01% 3319
2020
Q2 		$962K Buy
+12,300
New +$814K ﹤0.01% 4115
2016
Q4 		– Sell
-8,000
Closed -$568K – 4510
2016
Q3 		$568K Buy
+8,000
New +$511K ﹤0.01% 2635

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Jane Street's RARE Position: Q2 2026 in Review

Jane Street sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 173,743 shares — an estimated $4.32M sold.

Jane Street first reported a position in RARE in Q2 2015 and held it in 33 quarters. The position peaked at $23.5M in Q4 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Jane Street reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 173,743 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $4.32M.
  • Jane Street first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and held it in 33 quarters.
  • Jane Street's Ultragenyx Pharmaceutical position peaked at $23.5M in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.